Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50results about "Stomach cancer vaccine" patented technology

Method for diagnosis of intestinal-type gastric tumors

InactiveUS20060105333A1Sensitive and specific and convenient diagnostic and prognostic methodReduced expression levelOrganic active ingredientsPeptide/protein ingredientsAbnormal tissue growthIntestinal type
Objective methods for detecting and diagnosing intestinal-type gastric cancers are described herein. Also described is method for predicting the presence or absence of lymph node metastasis (i.e., identifying the metastatic phenotype). In one embodiment, the diagnostic method involves the scoring of gene expression profiles that discriminate between lymph node positive tumors and lymph node negative tumors. The predictive score calculated acts as diagnostic indicator that can objectively indicate whether a sample tissue has the metastatic phenotype. The present invention further provides methods of diagnosing intestinal-type gastric cancer in a subject, methods of screening for therapeutic agents useful in the treatment of intestinal-type gastric cancer, methods of treating intestinal-type gastric cancer and method of vaccinating a subject against intestinal-type gastric cancer.
Owner:ONCOTHERAPY SCI INC

Specific chimeric antigen receptor T cell targeting nkg2dl, preparation method and application thereof

A specific chimeric antigen receptor targeting NKG2DL, its coding sequence, and modified immune response cells, as well as their preparation method and application. The modified immune response cells can effectively target and attack various tumor cells, especially positive tumor cells expressing NKG2DL, and can be used to prepare preparations for treating tumors.
Owner:NANJING KAEDI BIOTHERAPEUTICS LTD

CLDN18.2-targeted chimeric antigen receptor and composition and application of CLDN18.2-targeted chimeric antigen receptor

The invention relates to the field of biological medicines, in particular to a single-chain antibody specifically bound with CLDN18.2 and a chimeric antigen receptor (CAR) containing the single-chain antibody. The invention also relates to reconstructed immune cells expressing the CAR, or co-expressing the CAR and a further bioactive molecule (e.g., a PD-1 antibody or mIL-15), nucleic acid molecules encoding such CAR or co-expressed molecules, and methods of preparing the reconstructed immune cells. The invention also relates to application of the CAR and the immune cells in preventing and / or treating cancers such as gastric cancer, gastric adenocarcinoma and pancreatic cancer and a method for preventing and / or treating the cancers such as the gastric cancer, the gastric adenocarcinoma and the pancreatic cancer.
Owner:CHENGDU KELUN PRECISION BIOTECHNOLOGY CO LTD

USE OF IL-1beta BINDING ANTIBODIES

Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and / or prevention of cancer with at least partial inflammatory basis.
Owner:NOVARTIS AG +3

Double-chimeric antigen receptor, T cell and construction method and application thereof

The invention discloses a double-chimeric antigen receptor, a T cell and a construction method and an application thereof, which belong to the field of cellular immunotherapy of tumors. The inventionspecifically relates to a specific structure and a construction method of the double chimeric antigen receptor T cell (dCAR-T cell), and preliminarily discusses the in-vivo and in-vitro activity of the dCAR-T cell. The selected tumor-associated antigens are mesothelin and carcino-embryonic antigens, and researches show that the two tumor antigens can be simultaneously expressed on the surface of asolid tumor, such as pancreatic cancer. The invention discloses an antigen receptor. The in-vitro and in-vivo tests prove that the constructed dCAR-T cell can be permanently and effectively activatedonly under the condition that two antigens are simultaneously recognized, and has efficient anti-tumor activity, so that a specific tumor killing function can be exerted, and the application of CAR-Tcell immunotherapy is improved.
Owner:CHINA PHARM UNIV

ROBO1 CAR-NK cell carrying suicide gene as well as preparation method and application of ROBO1 CAR-NK cell

The invention discloses an ROBO1 CAR-NK cell carrying a suicide gene as well as a preparation method and application of the ROBO1 CAR-NK cell. In order to improve the safety and controllability of theCAR-NK therapy, a suicide gene switch element is integrated into a genome through a lentiviral transfection technology on the basis of the current ROBO1 CAR-NK cell to form the CAR-NK with the suicide gene. By adding the suicide gene, the CAR-NK cells can be better controlled, and the clinical safety is further improved.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD

Universal chimeric antigen receptor T cell targeting claudin 18.2, construction method and application of universal chimeric antigen receptor T cell

The invention relates to a universal chimeric antigen receptor T cell targeting claudin 18.2, a construction method and an application of the universal chimeric antigen receptor T cell, and belongs tothe technical field of molecular biomedicine. The invention provides a single-chain antibody targeting the claudin 18.2, and the chimeric antigen receptor T cell containing the single-chain antibodytargeting the claudin 18.2. The chimeric antigen receptor targeting the claudin 18.2 can specifically target the claudin 18.2, promote the amplification of the T cell in the body of a patient, efficiently and specifically kill tumor cells, and hardly cause damage to normal cells.
Owner:NANJING BIOHENG BIOTECH CO LTD

Antibody Constructs for CLDN18.2 and CD3

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Owner:AMGEN INC +1

Chimeric antigen receptor of cell for targeted expression of Claudin 18.2 and application of chimeric antigen receptor

ActiveCN113354739AEfficient killingStrong killing and cytokine release functionVirusesAntibody mimetics/scaffoldsAntigenSingle-Chain Antibodies
The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.
Owner:SHANGHAI LIFE SCI & TECH CO LTD

Tumor composite antigen, dendritic cell multivalent vaccine and application of dendritic cell multivalent vaccine

The invention discloses a tumor composite antigen, a dendritic cell multivalent vaccine and application of the tumor composite antigen and the dendritic cell multivalent vaccine. Dendritic cells of a patient are stimulated in vitro, multiple tumor cell lysates with super immunogenicity aiming at different EBV related tumors are loaded, mature dendritic cells are formed under induction of multiple cell factors and specific agonists, a complete DC vaccine with corresponding cancer antigens is formed, the DC vaccine is transfused back to a human body to activate an immune system, and the EBV related tumors are subjected to tumor immunogenicity. Natural immunity (such as induction of NK cells) is stimulated, lymphocytes are stimulated to generate acquired immune response, cytotoxic T cells are generated to kill cancer cells, and the cancer cells are accurately killed together; compared with radiotherapy and chemotherapy, the composition is particularly safe and almost has no side effect; and the dendritic cell vaccine has a preparation cycle of about 1 week, and is short in time and low in cost.
Owner:刘慧宁 +1

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

Chimeric antigen receptor and use thereof

Provided is a chimeric antigen receptor, which comprises a co-stimulatory signal domain composed of an extracellular domain, a transmembrane domain and an intracellular domain, wherein the co-stimulatory signal domain comprises the full length or a fragment of the amino acids of encoded reverse dectin-1 and can treat multiple solid tumors and malignant hematological tumors.
Owner:SICHUAN UNIV

Anti-PD-L1/OX40 bispecific antibody preparation as well as preparation method and application thereof

The present invention relates to formulations comprising an anti-PD-L1 / OX40 bispecific antibody, in particular to pharmaceutical formulations comprising an anti-PD-L1 / OX40 bispecific antibody, a buffer, a stabilizer and a surfactant. In addition, the invention also relates to the use of these formulations for the treatment or prevention of diseases.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

A vaccine composition and uses thereof

The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. and wherein the at least one fusion peptide comprises two or more non- contiguous B cell epitopes of Her2 / neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and / or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2 / neu in a patient in need thereof.
Owner:BIOLIFE SCI QLD

IL-1[beta] binding antibodies for use in treating cancer

Use of an IL-1[beta] binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for thetreatment and / or prevention of cancer with at least partial inflammatory basis.
Owner:NOVARTIS AG

Specific chimeric antigen receptor cell armed with targeted CXCR2 ligand as well as preparation method and application thereof

The invention relates to a specific chimeric antigen receptor cell armed with a targeted CXCR2 ligand as well as a preparation method and application thereof. Through a method, which uses a recombinant carrier of a chimeric antigen receptor that specifically targets human NKG2DL armed with a targeting CXCR2 ligand to modify a immune response cell, the obtained novel functionalized immune responsecell can effectively attack multiple tumors in a targeted mode; and the functionalized immune response cell can be used to prepare preparations for treating malignant tumors. The engineering immune cells modified by a chimeric antigen receptor that is armed with a targeting CXCR2 ligand and specifically targets human NKG2DL can more easily migrate to a tumor position and continuously kill the tumors in a targeted mode.
Owner:NANJING KAEDI BIOTHERAPEUTICS LTD

Peptide vaccines

The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering the pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.
Owner:特雷斯生物有限公司

Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs

From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.
Owner:YMMUNOBIO AG

A33 antibody compositions and methods of using the same in radioimmunotherapy

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. Theantibodies of the present technology are useful in methods for detecting and treating an A33 -positive cancer in a subject in need thereof.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Anti-claudin 18 antibodies and methods of use thereof

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.
Owner:NOVAROCK BIOTHERAPEUTICS LTD

Vaccine composition and uses thereof

The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. 1007216A) and wherein the at least one fusion peptide comprises two or more non-contiguous B cell epitopes of Her2 / neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and / or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2 / neu in a patient in need thereof.
Owner:BIOLIFE SCI QLD

Inflammasome activators and methods of use to treat tumors

ActiveUS20180243390A1Effective anti-tumor immune responseIntestine cancer vaccineViral antigen ingredientsTumor regressionWilms' tumor
Compositions and treatments for inducing tumor regression by activating inflammasomes in tumor cells and tumor-associated cells. A tumor in a subject is treated by administering a composition to the subject that activates inflammasomes in cells of the tumor and thereby causes tumor cell pyroptosis and tumor regression.
Owner:LOYOLA UNIV OF CHICAGO

Composition of tumor-associated proliferative peptides and related Anti-cancer immunogen for the treatment of lung cancers and other cancers

The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.
Owner:ONKOLOGIX

Preparation method of Mesothelin chimeric antigen receptor modified T cell with targeted high-intensity tumor killing activity

The invention relates to a preparation method of Mesothelin chimeric antigen receptor modified T cells with targeted high-intensity tumor killing activity, which comprises the following steps: transforming MSLN-CAR-puro plasmids into escherichia coli competent cells, conducting coating, screening and culturing on a solid culture medium, and extracting plasmids after propagating a grown single colony; preparing human peripheral blood mononuclear lymphocytes (PBMCs); and extracting plasmids, mixing the extracted plasmids, Super PiggyBac Transspoase plasmids and an electrotransfection buffer solution, transfecting PBMC (peripheral blood mononuclear cells), conducting culturing by using an X-VIVO culture medium, activating and amplifying CD3 positive T cells by using CD3 / CD28 magnetic beads, and screening and amplifying the transfected T cells. The mesothelin-targeted MSLN-CAR-T cell is constructed through a PiggyBac transposon system, so that the mesothelin-targeted MSLN-CAR-T cell has targeted killing performance on solid tumors and is good in safety, and a research basis is provided for related clinical transformation.
Owner:YANAN HOSPITAL OF KUNMING CITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products